Wells Fargo & Company Longboard Pharmaceuticals, Inc. Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding LBPH
# of Institutions
109Shares Held
35.2MCall Options Held
8.5KPut Options Held
31.1K-
Ra Capital Management, L.P. Boston, MA3.29MShares$197 Million1.34% of portfolio
-
Farallon Capital Management LLC San Francisco, CA2.94MShares$176 Million0.38% of portfolio
-
Cormorant Asset Management, LP Boston, MA2.79MShares$167 Million5.8% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.51MShares$150 Million0.01% of portfolio
-
Black Rock Inc. New York, NY2.37MShares$142 Million0.0% of portfolio
About Longboard Pharmaceuticals, Inc.
- Ticker LBPH
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 13,586,000
- Market Cap $814M
- Description
- Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical ...